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Abstract
Background: The emergence of resistance to the first line Antiretroviral therapy (ART) leads to
a need for more expensive and less tolerable second line drugs. Therefore it is essential to
identify factors associated with increased probability of treatment failure.
Objectives: The aim of this study was to assess clinical and immunologic failure of first line
treatment failure in children and time of switch to second line drugs.
Method: A retrospective cohort study was conducted with chart review of all HIV-infected
children less than 15 years of age, who took HAART for at least six months in the major
hospitals of Addis Ababa. Data was collected, entered and analyzed using Epi info version 3.5.1,
SPSS version 16 and Smart soft ware 2008. The Cox proportional-hazards model was then used
to assess the predictors of factors associated with treatment failure.
Result: A sample size of 1186 children was evaluated. Five hundred seventy seven (48.7%) were
male and 609 (51.3%) were female with mean age of 74(±37SD) months.  Out of 167(14.1%)
children who had treatment failure, 80 (6.7%) had clinical failure, 87 (7.3%) immunologic
failure and 18 (1.5%) had both. Patients who had height for age less than -3 z-score(ZS ) with
adjusted hazard ratio(AHR) of 0.429 95% CI(0.291-0.632) were found to have high probability
of treatment failure. Patients with base line CD4 count below 50 (AHR=2.009(1.194-3.380));
with presence of chronic diarrhea after start of ART (AHR= 3.439(1.372-8.623)) and with drug
substitution (AHR=1.695(1.053-2.728)) were also found to be at risk. From all treatment
failures, only 24(14.37%) of patients were switched to second line with a mean delay of
24±31.67SD month.
Conclusions: Having chronic malnutrition and low CD4 at base line and chronic diarrhea after
the start of ART and substitution of drug were found to be predictors of treatment failure in
children. Most of the treatment failure were not detected and are not switched to second line
Recommendation:   monitoring of children for treatment failure with the above predictors and
timely switch to second line is mandatory.
11 Introduction
The HIV epidemic continues to be a major challenge to global health. According to the 2009
UNAIDS report, about 33.4 million people are living with HIV (LWHA) all over the world and
out of them 2.1 million are children . In 2008 alone, 430, 000 children under 15 year of age were
newly infected and 280, 000 lost their lives because of AIDS (1). Sub-Saharan Africa remains
the region mostly affected by HIV; where 90% of new HIV infections among children occurred.
Approximately 7 out of 10 deaths recorded were in this region (1, 2).
Despite the fact that the number of children receiving ART globally  increased from around 75,
000 in 2005 to almost to 360, 000 in  2009 (3),Pediatric ART still lags behind as children
account for only 6%  of the total ART patients. Only one in seven of the 780,000 children in
need of ART are receiving it (4). Between 2008 and 2009 in sub-Saharan Africa, the estimated
number of children receiving ART rose from 224, 100 to 296,000. Total ART coverage was
estimated about 26% (5).
In Ethiopia, in 2006 an estimated 134,000 children less than 15 years of age were LWHA; 2009
National pediatric Cumulative patient ever enrolled in HIV care were 29,546 and cumulative
ever Started ART are 13,650. Children who were on first line regimen were 10,361, while
children on second line were only 135 cases; which showed slight increase from 2005 i.e. 10
cases only (6, 7).
Antiretroviral drugs (ARV) are drugs used lifelong to suppress the viral replication which  limit
the weakening of the immune system .Taking two or more drugs at a time is known as
combination therapy and if combination is three or more, it is referred  as to Highly Active
Antiretroviral Therapy (HAART)(8).
Many studies report the success of HAART in improving clinical and immunologic outcome of
children (9-13). But as the rate of HAART coverage increases, drug resistance with subsequent
treatment failure starts to emerge simultaneously. Theses treatment failure in children could be
due to clinical, immunological or virological failure (14-16).
21.2. Rationale of the study
Though HAART has resulted decrement in morbidity and mortality (13); keeping patients on
such lifelong drug with monitoring of different investigations is extremely expensive in
developing countries. Furthermore, the emergence of resistance leads to treatment failure and a
need for second line drugs. These second line drugs are said to be more expensive and have
increased side effects and decreased tolerability than the first line (14, 17). In addition treatment
failure leads to reemergence opportunistic infection with all its consequences of social, economic
constrains in the family and to the whole community. Even though it is very costly to shift to
second-line ART, late switching to second-line ART is expected to result in greater resistance
and may limit the effectiveness of second-line regimens (16).
Therefore, addressing the predictors associated with treatment failure in order to be able to
prevent it is very important. However, there is limited data on children who have treatment
failure, the associated factors and the timing of shift to second line drugs .This is a concern for
subsequent ART management, quality of life and long term outcome of children living with HIV.
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2.1 Overview of the HAART Impact
Since the introduction of HAART, HIV related morbidity and mortality have noticeably declined
(13). The benefits of HAART in promoting growth and maintaining prolonged health have been
consistently shown in several studies (9-13). This has been demonstrated by the Ugandan
prospective cohort, which showed growth increment increased after 48 weeks of therapy (9).
Another study from the Netherlands also showed an increment in weight, height and Body mass
index (BMI) (10). In Cambodia and other studies continually revealed Opportunistic Infections
(OI), diarrhea and pneumonia are becoming uncommon in the HAART era compared with the
pre-HAART era (9-13, 18).
2.2 ART Treatment Failure
Once patients are started on ART, they generally remain on medications indefinitely. A change
in the first-line ART regimen is often necessary because of a number of reasons among which
first-line ART failure is one. Treatment failure in children can be due to clinical, immunological
or Virologic Failure (14-16).
Clinical failure: is defined as either of the following:
1. Occurrences of new Opportunistic infections (OIs)  or malignancies  or
2. Failure to sustain growth rate in  a child who had showed response initially
3. Loss of neurodevelopment milestones excluding other causes (14-16).
If the reason for considering treatment failure is growth failure; nutrition therapy should be
insured first. Before labeling clinical failure, it is also recommended that a child with pulmonary
or lymph node TB be treated. (14, 16)
4Immunologic failure: is defined as arpid rate of decline to at or below to the sever
immunodeficiency state for age as seen in Table 1or a fall in CD4 50% of the peak without other
conditions or causes (14,16). It is required to have at least two CD4 measurements before
defining for treatment failure and switching   (14). Generally treatment failure should be
differentiated from immune Reconstitution syndrome (IRS) which is a paradoxical  clinical
deterioration while  the immune system begins to improve in contrast to treatment failure where
immunologic  improvement is usually failed to demonstrate(14,19).
Table 1 Age related immunologic classification
HIV associated
immunodeficiency
CD4 percentage≤59month or count>59month
<11mo 12-35mo 36-59mo 5yrs &above
Not significant >35 >30 >25 >500
mild 30-35 25-30 20-25 350-499
advanced 25-30 20-25 15-20 200-349
severe <25 <20 <15 <200 or <15%
Virologic failure: thresholds in children are not yet clear. Levels more than 100,000 copies are
required to switch treatment. Routine viral load measurement has not been recommended in
resource limited countries unless conflicting correlation b/n clinical and immunologic failure
because of the cost and ambiguity of its interpretation (14).
52.3 Magnitude of first-line ART failure
Despite the relatively limited pediatric ART coverage, studies now demonstrate that as more
children accessed the antiretroviral treatment, a simultaneous increase in the number of treatment
failures occurred, and requiring second-line treatment. A systematic review of first-line ART
failure and attrition rates in resource constrained settings revealed different rates of first-line
ART failure among studies using clinical criteria only or immunological criteria and those use
virology criteria in adult studies (20-22).
2.4 Predictors of treatment failure
There are many factors that increase the likelihood of first-line ART failure. Inadequate
adherence to treatment, drug side-effects and toxicity leading to poor adherence to treatment,
Socio demographic  factors such as age ,sex , being an orphan , baseline patient factors (e.g. high
pre-treatment viral load, low pre-treatment CD4 Count, prior WHO staging and drug-drug
interactions between the antiretroviral drugs and other concomitantly administered drugs
resulting in sub-therapeutic drug concentrations are among the commonest factors increasing the
probability of occurrence of first-line ART failure (23-31).
The primary factor associated with poor treatment outcome is in fact poor adherence to treatment
which is in turn associated with many factors such as not enough drug  at home, caregivers being
away; the caregiver’s educational status; frequency of visit to the clinic; distance traveled to the
clinic; drug formulation, regimen type and duration of HAART usage, financial constrains,
missed clinic appointments, child refusal or self-discontinued, and gender (23-27).
Another factor associated with treatment failure is higher initial viral loads and severe
immunologic suppression during the start of ART. As the African study demonstrates, a viral
load greater than a million copies per ml is associated with virologic failure (32). Studies done in
Uganda, South Africa, Thailand and Zambia showed that delay in starting of HAART with
severe immunologic suppression is also another predictor of first-line ART failure that should be
looked for (20,28) . Therefore, earlier intervention is demanded since mortality during the early
days of therapy is high. Most of the deaths recorded within 19 days of ART initiation in Uganda,
5 months in South Africa and three months in Jimma, Ethiopia (20.23, 31).
6The other predictors of treatment failure mentioned are age and sex of the child. A cohort study
in Thailand showed younger age was found to be predictors for immune recovery (30). In the
UK and Ireland though the immunological response is better in younger children, poorer
virological response and increasing the risk of resistance was documented (33). Similarly, in the
South African and Tanzanian study younger age is associated with virologic failure (28,34). In a
study conducted at Makerere University in Kampala the independent predictor documented was
male gender similarly the Thailand study showed better immune recovery in female gender (20,
30).
The Cambodia cohort study, including a cross-sectional evaluation of virologic status of 212 who
took a 12 month of HAART before the study period showed being an orphan is statically
associated with virologic failure (18). Other predictors associated with treatment failure in other
studies were inadequate dose adjustment leading to sub optimal dose, drug toxicity with
subsequent treatment discontinuation and occurrence of opportunistic infection. Regiment type
also has effect as demonstrated in Tanzania study.(34,35) Malawi and Ethiopia studies
additionally suggest that chronic gastroenteritis which decreases absorption of the drugs as one
of the risk factor for treatment failure (26, 31).
Uganda, Zambia, South Africa , Côte d'Ivoire studies revealed that though the overall
immunological and virologic responses are similar in resource limited and resource rich
countries; but the CD4 recovery rate  and growth responses have been documented to be slow  in
resource limited countries. This could be because of associated higher background malnutrition,
infection rates and long travel times to access care. This suggests that in sub-Saharan Africa
there is a need for low price diagnostic tests for earlier identification of HIV infection in infants,
improved access to ART programmers, including extension of care to remote areas and the
integration of ART programs with other health-care services, such as nutritional support (18, 20,
27, 36 and 37).
72.5 The probability of treatment failure and time of switch
In a South African retrospective cohort study of 151 patients 9.9% have progressed to a second
line, one (0.7%) to a third line, and one (0.7%) to a fourth line.  Antiretroviral drug resistance
was detected in more than 80% of KwaZulu Natal South African patients with a detectable
HAART drug resistance which predicts failure of a first HAART regimen (33). The probability
of failure after a year of first line ART regimen in Malawi was 1.6% (26).
A south African study using the international epidemiologic databases of 5484 children with
median follow up of  16  months reported Virologic failure in  310 children with cumulative
probability of (11.4%) , 146 were switched with cumulative probability of 6% at 3 years but
50% of the children with virologic failure were not switched to second-line antiretroviral therapy
(ART) and, for those who did receive second-line treatment, a delay of close to five months
between failures and switching occurred (28). The retrospective study in Malawi demonstrated
the average time on ART before shifting to second-line ART regimen was 16.3 months and of
the total 1434 patients who were eligible, only 22 patients (1.5%) were on a second-line regimen
due to ART failure.  In South Africa the median time between virologic failure and switch is 4.6
months (26).
2.6 Situation of treatment failure in the study setting
Ethiopia’s first pediatric HIV/AIDS situational analysis revealed many barriers for the care and
support of pediatric HIV patients. Only 28% of pregnant women in Ethiopia have antenatal care
with only10% institutional delivery, therefore, diagnosing pediatric HIV infection early and
initiation of timely ART is hampered. Antiretroviral therapy started according to National
guideline adopted from WHO. Routine virologic examination is limited. Children who are in
second line treatment were only 10 in 2005 and currently 135 nationwide (6, 7).
According to a three -year’s retrospective Cohort analysis at Jimma University, Ethiopia reported
Clinical treatment failure in 6.2% patients and immunologic treatment failure in 11.5% of the
patients. Presence of chronic gastroenteritis, appearance of new opportunistic infection after
8starting treatment were associated with immunologic treatment failure. Deaths that occurred
within the first three months of therapy were associated with higher rate of defaulters, treatment
failure, severe drug toxicity and regimen change (31).
Regarding the predictors of treatment failure in an Ethiopian context, detailed studies are rare.
The study done in Ethiopian children on adherence to ART in Addis Ababa in five major
hospitals, namely Tikur Anbessa Generalized Specialized Hospital, Saint Peter Hospital, Yekatit
12 Hospital, and Zewditu Memorial Hospital showed adherence rate of 93% in the past 3 days
and 87% in the past 7 days before the date of interview and it is acceptably higher than other
similar setups (22).
93 Objective of the study
3.1 General objective:
The aim of this study is to identify the clinical, immunologic failure of pediatric patients who
have been using highly active antiretroviral therapy (HAART) for more than six months in
selected Hospitals of Addis Ababa Ethiopia.
Specific objectives:
3.1.1 To determine the magnitude of clinical treatment failures
3.1.2 To determine the magnitude of immunologic treatment failures
3.1.3 To identify predictors of treatment failures
Secondary objective:
To estimate the magnitude of patients with treatment failure but still on first
line drug (not switched to second line)
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4 Methodology
4.1 Study setting
The study was carried out in Addis Ababa, the capital city of Ethiopia .The city area is 450
square kilometer with estimated 2.7 million populations. The four major public pediatric referral
hospitals namely Tikur Anbessa, Yekatit 12, Zewditu Memorial and Alert hospital were selected
for this study. Those hospitals were selected because they have been providing ART service for
more than a year and a prior pediatric adherence study was done in this setting and furthermore
these hospitals are also providing second line ART. A total number of children on ART in these
hospitals are greater than 50% (ie 1.732) of the total children in all Addis Ababa public hospitals
i.e. 2041(38). ALERT Hospital is under the Federal Ministry of Health. Yekatit 12 and Zewditu
Memorial hospitals are under the Addis Ababa Regional Health Bureau, while Tikur Anbessa is
under Addis Ababa University.
4.2 Study Design
The study design utilized for this study was a retrospective cohort study.
4.3 Source population
All children under the age of 15years who are on  ART and living in Addis Ababa, Ethiopia.
4.4 Study subjects:
The study population was all HIV infected children who started Anti Retroviral Treatment
between March 2005 and March 2011 in the four selected hospitals namely, Tikuer Anbessa
Specialized, Zewditu Memorial, Yekatit 12 and ALERT hospitals.
4.5 Sample Size
I. For the first objective of this study is the formula for estimating single population proportion
given below was used to calculate the required sample size.
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Where, p is the expected percent of children who have treatment failure and d is the absolute
precision. In this case, from literatures reviewed, immunologic failure is approximately 11.5%.
p= 0.11 is and assuming d=0.02, the required sample size will be 459. Adding a non-response
rate for incorrect documentation of records 10% i.e. 46, the calculated sample size by this
method will be 505 (31, 39).
Table 2: Sample size Determination
Variables P d Sample size
calculated
Total including 10% for
improper
documentation
Clinical treatment failure 6.2% 2% 248 273
Immunologic failure 11.5% 2% 418 459
II. To determine the required sample size for the second objective which is to determine the
predictive factors for treatment failure, the two population proportion formula given below will
be used.
n 1 = Zα/2√ [1 + 1/r]p(1-p)+Zβ√p1(1-p1 )+p2(1-p2 )/r 2
(p1 –p2)2
Where
n1 = the required sample size for the treatment failures with predicting factor
n2= the required sample size for treatment failure with no predicting factors
n1:n2 = 1:3
p1= Proportion of predicting factors in treatment failure
p2= Proportion of absence predicting factor in treatment failure
P = p1 +rp2
1+r
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α= Type-I error (0.05)
Zα/2= Critical value at 95% level of confidence 6
Zβ = standard normal distribution value corresponding to power 84
Table 3: Sample size determination with two proportion sampling method
Variable Sample size
for treatment
failure with
predictors :n
Sample size for
treatment failure
with no
predictors: 3 n
Total sample size
including 10% for
improper documentation
Proportion
Of Adherence in treatment
failures
95.0%
286 859 1,259
Proportion
Of non Adherence in
treatment failure
99.4%
Proportion of high
CD4 in treatment failure
29.9
109 218 360Proportion of low CD4 in
non treatment failure
15.7
Proportion EFV-based
regimen compared in
treatment failure
17.5%
127 381 608
Proportion of none EFv
based regimen in
treatment failure
44.4%
Proportion of NVP-based
regimen  in treatment
failure
82.5%
84 252 672
None Nvp- based regimen
in non treatment failure
(55.6%)
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From the possible common predictors of treatment failure adherence yields the higher number,
therefore, sample size of   1,259 was calculated considering the visibility of this study in the
allocated time.
4.6 Sampling procedure
The sample was proportionally allocated to each Hospital based on the number of pediatrics
ART enrolled patients. Systematic random sampling technique was done at each hospital to
identify the study subjects using the ART unique numbers from the registration book. But since
the sample size was not reached finally all children who fulfilled inclusion criteria were used,
except those with poor documentation See Fig 1.
Figure 1: Diagram for sampling procedure
Inclusion Criteria
 Children who started HAART  at least 6 month before the time of the survey
 Children age under 15 years of age since above 15 are referred to adult clinic
 Children taking triple ART drugs
 Children on HAART with at least two  follow up visits
Children on ART for at least t 6 month who fulfill inclusion
criteria =n
ALERT
215(18.1)
Zewditu
315(26.6)
All children enrolled in HIV care
Tikur ANbessa
252(21.2)
Yekatit
404(34.1)
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Exclusion Criteria:
 Children who took ART only for PMTCT purpose
 Children who don’t have two follow up visits after ART
4.7 Data collection Procedures
The sources of data for this study were the Pre-ART register, the ART register and the patients’
ART follow up and medical charts. In those registers and follow up charts, clients’ socio
demographic, clinical and laboratory information, treatments being provided, the follow up status
of each client are recorded (Annex I). Data was collected using a structured checklist for records
review developed from the registers and follow up charts. Since the registers are prepared in
English, the checklist is also prepared in English.
4.8 Variables of the Study
4.8.1 Dependent Variable
The dependent variable to be studied is the outcome of first-line pediatric ART in terms of
clinical failure and immunologic failure.
4.8.2 Independent Variables
The independent variables of this study are socio demographic factors such as age, sex, care-
giver HIV status, whether the child is orphan or not, baseline clinical and laboratory data of
patients such as WHO Clinical stage ,CD4 Count or CD4% at the start of ART, adherence level,
presence of chronic diarrhea  after ART, nutritional status at the start of ART, presence or
development of drug-side effects  and drug substitution ,  prior PMTCT drug exposure,  drug
form, and the ART regimen used.
4.9 Data Management
Data was collected by nurses trained on pediatric HIV care and support, and who have been
working in ART clinic of the respective hospitals. They were trained by the primary investigator
about the data to be collected from the patient cards through the questionnaire and they were
supervised throughout data collection process. The questioner was retested before the actual data
collection. The data was collected in the health facilities starting from Dec 2010 to March 2011
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until the sample size was saturated. Five percent of the data cross checked for completeness,
accuracy, and consistency before entry to software program and accordingly adjustments was
made. During data entry double entering was done for 5% of the check lists.
4.10 Data Entry and analysis
The data was entered and analyzed using software programs Epi info version 3.5.1, and SPSS
version 16.Anthropometric measurement was analyzed with Smart soft ware version 3.2.2.
Descriptive statistics as range, means with standard deviations (SD) were generated and cox
regresstion we association between the outcome and the independent variables were taken as
significant at p= 0.05. Moreover, treatment failure rate along with 95% CI were estimated.  First-
line ART failures were described by subcategories of demographic and clinical characteristics.
Independent variables that were significantly associated with first-line ART failure in bi-variante
analysis were further examined in multivariate analysis. The Cox proportional-hazards model
was used to assess the predictors of factors associated with treatment failure. Kaplan-Meier
survival methods were used to estimate the probability of treatment failure
4.11 Operational Definitions
Regimen changes: replacement of the first antiretroviral regimen by another in the same
regimen
First line ART: is the original drug regimen used as the national guideline with combination of
two NRTIs and one NNRTI.
Second-line ART: is the regimen used immediately after first-line therapy.
Switch:  Regimen Change from the first line to second line or to third-line.
Substitution: This refers to the replacement of one of the antiretroviral drug by another in the
same regimen.
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Clinical failure: is defined as having either growth failure ;or  developmental delay or
regression) or occurrence of new or recurrent WHO clinical Stage IV.
Growth failure: is defined below -3Zscor of NCHS curve any time after 6 month of ART and
if this growth failure persists for another six month .Additional six month was used assuming if the
growth failure is due to nutritional it can be treated on the next 6 month after treatment failure identified.
Immunological treatment failure:  defined as achievement of a CD4 cell percent or count
below the cut off level for age (CD4 cell percent; less than one year< 25%, one to five years <
20%, greater than five years <15%) after 24 weeks of HAART or .
The children are classified into: Immunological failure (IF), clinical failure (CF) and both
clinical and immunological failure (CF and IF).
Primary care giver – a person responsible for giving the child living and administration of
his/her drugs and also who brought the child to the follow up. The person could change over
time.
Adherence: for this study the report of the status of adherence on ART follow up chart was used
Participants were classified as
1. Good adherence: are those with good adherence documented throughout the follow up
2. Faire - Those patients with one episode of poor adherence documented
3. Poor adherence:  More than two episode of poor adherence documented
4.12 Ethical consideration
Ethical approval was sought from University of Gonder and Addis Continental Institute of Public
Health and from Alert review committee .The study institutions were informed the purpose of the
study through supporting letter from UGACIP and the Addis Ababa Regional Health Bureau
Bero.  Confidentiality of patient information was kept by the investigator and data collectors and
names of the patient and patient information was omitted from the structured questionnaire.
Personal data obtained was accessible to primary investigators and was stored in secured area.
The confidentiality will still be kept in dissemination of the result as well. Due to the retrospective
and chart review nature of the study; informed consent was gained from each hospital rather than
individual patients (Annex II and Annex III).
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5 Result of the study
The number of patients who were on first line ART for at least six months and less than 15 years
of age were 1,220 from which 1,186 Pediatric patients were studied and 34 were excluded
because of incomplete documentation. From the 1,186 in the sample, 608 (48.8%) are female
while   578 (51.2%) are male. The mean age at initiation of ART was 74.6±37.3SD months and
range (2 -172) months. The primary care takers were both parents for 35% of the patients while
only one of the parents (either mother or father) in 33.7%. Percentage of patients under the care
of relatives is 10.5%, Orphanage and guardians were 8.3 and 12.0% respectively. Nearly 25 % of
children lost there both parents   and   43.45 % of them either parents. Only 2.4% of children had
PMTCT and received infant prophylaxis (Nvp only 0.8% and NVp+Zdv 1.6%) see Table 4.
Regarding the base line data during initiation of ART nearly 71% of the patients were in WHO
clinical stage III and IV while those in stage I and II were 3.5% and 25.7% respectively. Severe
and advanced immunologic deficiency at the time of start was found in71.9%. The reason for the
start of ART was WHO clinical staging in 210 (17.7%), CD4 count in 248 (20.9%) and both
WHO and immunologic for 719 (60.6%) of the patients and 9(0.7%) of the patients age less than
one year was used as a criteria to start ART. The regimen type initiated at base line was
Neverapine based in 688 (58%) and Efaverense based 467(39.3%) see Table 4.
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Table 4: the socio Demographic and clinical characteristics of children on HAART in selected
Hospitals of Addis Ababa, 2011.
Characteristics Number (%)
Age
≤ 11 months 46( )
11 to 34 169 (14.2)
34 to 59 212 (17.9)
≥60 month 759 (64)
Sex (n=1186)
Female 608 (48.8%)
male 578 (51.2%)
Hospital (n=1186)
Alert 215(18.1)
yekatit 252 (21.2)
Tikur Anbessa 404 (34.1)
Zewditu Memorial 315 (26.6)
Parental status n=1155
Both alive 427(36.96)
Either dead 468(40.51)
Both  dead 260(22.5)
Primary care taker
Both parents
Mother
Father
Relatives
Guardians /neighbors
Orphange
415(35)
249(21)
156(13.2)
125(10.5)
142(12)
99(8.3)
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Characteristics Number (%)
Serology of the care takers
Positive 773(65.2)
Negative 55(4.6)
Unknown 358(30.2)
Parental status
Both alive
Either dead
Both  dead
WHO stage(n=1186)
I 42(3.5)
II 305(25.7)
III 626(52.8)
IV 213(18)
Regimen started initially
4a( DRT+3TC+NVP) 388(32.7)
4b(DRT+3TC+EVS) 106(8.9)
4c(AZT+3TC+NVP) 300(25.3)
4d(AZT+3Tc+Evs) 361(30.4)
Other 31(2.6)
Infant ART prophylaxis
NVP 9(0.8)
NVP+ZDV 19(1.6)
None 977(82.4)
Unknown 181(15.3)
Tb after ART (n=1186) 36(3%)
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A significant number of children were malnourished at base line  that is weight for age, height
for age and weight for height was less than -3zs for 14.5%, 27.9% and 2.4% of the patients
respectively .During the start of ART 400( 33.7%) children were having sever immunodeficiency
State based on either CD4 percentage in under 5 or CD4 count in above 5 year of age. The CD4
count was less than 50 in 80 (6.74%) of all children see Table 5.
Table 5:  Socio-demographic and clinical characteristics of treatment failures and treatment
success groups in children on HAART in Addis Ababa, 2011
Covariant Treatment
failure
Number
Treatment
success
number
Crude HR (95%CI) Adjusted HR (95%CI)
Age (month)
age ≤11 9(5.4) 37(3.6) 1.036(0.504-2.128)**
age 11-34 36(21.6 ) 131(12.9) 1.13(0.724-1.764)
age 35-59 29(17.4) 190(18.2) 0.632(0.393-1.015)
age: 60 to 108 51(30.5) 473(46.9) 0.454(0.301-0.685)**
age> 109 42(25.1) 193(18.9) 1
Sex (n=1186)
Female 71(42.5) 506(49.7) 0.785(0.577-1.069)
male 96(57.5) 512 (50.3) 1
Primary care taker
Both parents 65(38.9) 350(34.3) 1.113(0.635-1.952)
Mother 28(16.8) 221(21.7) 0.768(0.410-1.438)
Father 26(15.6) 130(12.8) 1.049(0.553-1.990)
Relatives 18(10.8) 107(10.5) 0.937(0.472-1.859)
Guardians/neighbours 15(9) 127( 12.5) 0.709(0.346-1.450)
Orphanage 15(9) 84(8.2) 1
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Covariant Treatment
failure
Number
Treatment
success
number
Crude HR (95%CI) Adjusted HR (95%CI)
Sero status of care takers
Positive 112(67.1) 661(64.9) 1.122(0.798-1.578
Negative 8(4.8 ) 47(4.6 ) 0.94(0.409-2.001)
Unknown 47(28.1 ) 311( 30.5) 1
Adherence level
Good 162(97) 1006(98.7) 0.450( 0.111-1.814)
faire 3(1.8) 8(0.8) 0.843( 0.141-5.052)
poor 2(1.2) 5(0.5) 1
Weight for age at ART0
≤-3zs 52(31.5) 120(11.8) 2.385(1.024-5.553)*
_-3zs -+3zs 107(64.8) 856(84.4) 0.813(0.357-1.852)
≥3zs 6(3.6) 38(3.7) 1
Height for age at ART )
≤-3zs 88(53.7) 239(23.7) 2.223(1.156-4.276)* 0.429(0.291-0.632)**
-3zs -+3zs 66(40.2) 697(69.2) 0.653(0.336-1.271)
≥ +3Zs 10(6.1) 71(7.1) 1
Weight for height NCHS
>-1Zscore 6(4) 20(2.2) 1.926(0.844-4.404)
-1to -2Z score 9(6) 70(7.7) 0.927(0.468-1.937)
<-2Z score 41(27.5) 204(22.5) 1
<-3 Zscore 93(62.4) 614(67.6)
22
Covariant Treatment
failure
Number
Treatment
success
number
Crude HR (95%CI) Adjusted HR (95%CI)
WHO clinical stage on
HAART initiation
Stage 1 7(4.2) 35(3.4) 1.324(0.587-2.984)
Stage 2 46(27.5) 259(25.4) 1.059(0.681-1.644)
Stage 3 79(47.3) 547(53.7) 0.809(0.543-1.205)
Stage 4 35(21) 178(17.5) 1
CD4 % or count at
ART start
Sever  immunodeficiency 67(41.9) 383(41.4) 0.711(0.464-1.089)
Advanced immunodeficiency 43(26.9) 288(31.1) 0.652(0.411-1.035)
Mild immunodeficiency 19(11.9) 126(13.6) 0.620(0.350-1.098)
No immunodeficiency 31(19.4) 129(13.9) 1
CD4 at initiation
>50 112(85.5) 859(93.4) 1.930(1.173-3.176)* 2.009(1.194-3.380)**
≤50 19(14.5) 61(6.6)
PMTCT for mother
Present 3(1.8) 21(2.1) 1.268(0.394-4.086)
None 119(71.3) 705(69.2) 1.196(0.848-1.687)
unknown 45(26.9) 293(28.80 1
Disclosure
Disclosed 41(36) 270(35) 0.971(0.660-1.428)
Not disclosed 73(64) 501(65) 1
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Covariant Treatment
failure
Number
Treatment
success
number
Crude HR (95%CI) Adjusted HR (95%CI)
ART infant prophylaxis
NVP only 1(0.6) 8(0.8) 1.454(0.194-10.896)
NVP+ZDV 4(2.4) 15(1.5) 2.99(1.010-6.849)*
None 144(86.2) 833(81.7) 1.720(1.053-2.810)*
HAART regimen type
4a( DRT+3TC+NVP) 59(35.3) 329(32.3) 0.453(0.232-0.886)*
4b(DRT+3TC+EVS) 14(8.4) 92(9) 0.347(0.154-0.782)*
4c(AZT+3TC+NVP) 46(27.5) 254(24.9) 0.377(0.190-0.749)**
4d(AZT+3Tc+Evs) 38(22.8) 323(31.7) 0.245(0.122-0.493)**
other 10(6) 21(2.1) 1
Substitution of single drug
Present 138(82.6) 94(9.2) 0.501(0.336-0.0.748)** 1.695(1.053-2.728)*
Absent 29(17.4) 925(90.8) 1
Dose form
Fixed 9(5.4) 42(4.1) 1.268(0.394-4.086)
Separate 109(65.3) 600(58.9) 1.196(0.848-1.687)
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The mean follow up period after ART initiated was 37±17month with minimum 6month to
maximum of 74months.  Though high number of malnutrition observed at base line; a marked
increase in weight for height observed after 12 month of ART see Fig 2 and 3.
Figure 2:   weight for height at ART initiation month compared to the WHO Standard curve
Figure 3:  weight for height after ART 12 month compared to the WHO standard curve
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Similarly though large number of children were having sever immunodeficiency at base line  the
mean increment CD4 count is statically significant till 12 month after ART( p=0.000) then it
slops till 36 month of ART  with no statistically significant increment in CD4 and then  start to
decline after  42 month  this  is although it was not a statically significant decline  p=0.48 Fig 4
Figure 4: The mean CD4 count over 42 month of follow up.
Over all opportunistic infection incidences after the start of ART was 52  (4.4%)  the   mean
onset was (20.79-±15.914) months and the range(2month to 62 month) and the commonest
Opportunistic infection being Tb in 36 (3% ), 16(1.3%) chronic diarrhea more than two weeks, 2
of the patients had  peumocystic carina pneumonia,  2 recurrent intractable oral thrush , 1
recurrent severe pneumonia .
The overall adherence report  was good; with no episode of poor adherence being in 98.4% and
two or more episode of poor adherence was documented in 7 (0.6%) of the patients.
P = 0.000
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Anti-retroviral drug substitutions were done for 119 (90%) patients. The majority of substitution
was done for toxicity 94 (7.9%), 7(0.6%) for concomitant TB treatment, and for 4 (0.4%)
patients the causes of substitution were not specified.
Out of the 167 patients 80 (%) developed clinical treatment failure, 87(52%) of them
immunologic failure and 18 (10.77%) developed both immunologic and clinical failures. Clinical
failures due to developmental regression were 22(1.9%),due to growth failure and opportunistic
infection were 51(4.3%) an 35(3%) respectively.
Patients who had height for age greater than -3 z-score (ZS) with (AHR) of 0.429 95%CI(0.291-
0.632) were found to have less probability of treatment failure see figure 5. Compared to the
Patients with base line CD4 count above 50 those who had below 50 h higher probability of
treatment failure (AHR=2.009(1.194-3.380)) see Fig 6; Similarly the presence of chronic ve
diarrhea after start of ART (AHR= 3.439(1.372-8.623)) and with drug substitution
(AHR=1.695(1.053-2.728)) were also found to be at risk.(Fig 7 and 8)
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Figure 5: Cumulative probability of not having treatment failure in HAZ Categories
Figure 6: Cumulative probability of having treatment failure with CD4 count less than 50
P = 0.009
P = 0.00
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Figure 7: cumulative probability of treatment failure in Children where chronic diarrhea
present or absent after ART initiation
P = 0.002
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Figure 8: The cumulative probability of having treatment failure with and with drug
substitution
When we see the detection rate of treatment failure out of the 167 only 24 (i.e14.35%) treatment
failures were identified. The mean of treatment failures from the time ART started was 19.7 (±
14SD) months and the duration of time from treatment failure to second line for those switched
was 24±31.67month..
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Table 6: First line Treatment failures vs. switch to second line
Time of Treatment failure
Number of  Treatment
failures with first line
Treatment switched to  second line
Number 143 24month
Mean duration till
failure /switch
19.7(± 14SD)month 24±31.67month
Range 6-62 month(±16.7) 5-7month
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6 Discussions
This study found higher number of treatment failure patients (14.1% out of 167) clinical failure
are observed in 80(7%) and immunologic failure in 87(7.3%) and both in 18 (1.5%). only 24 of
them are labeled as treatment failure and switched to second line. This is in contrary to the
national report of only 135 pediatric patients put on second line drugs (6, 7, 41).This finding
demonstrates that a significant number of treatments failures are not identified and/or not
switched to second line.
The overall sex distribution is slightly higher for females than males (51.15 %vs 48.8%) this is
similar to the finding of the study in Jimma University (31). Although the Makerere University
and Chiang Mai, Thailand study which showed male sex as predictor of treatment failure , this
was not demonstrated in  our study( 20,30,). Similar to the Mekrere university which found
younger age was commented as a predictor of virologic failure, in our study the age group
<11month have higher risk than their older age counterparts (20, 30,34,40) on bivariat cox
regression but not demonstrated in multivariate analysis . Unlike the Jimma and the Cambodian
studies, there was no association of treatment failure was identified with being an orphan (18,
31).
Only 2.4 %( ie 0.8% took NVP only and 1.6% NVP+ZDV) for infant prophylaxis which could
be explained by the low Antenatal coverage 28% and institutional deliveries of the country (5%).
(7). Most of these HIV infections could have been prevented if these children had PMTCT
service. The majority of patients were having WHO stage 3 and 4 in 70.8% at initiation unlike
the Study in Jimma WHO clinical staging didn’t show increase in probability of treatment failure
(31).
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Adherence in this study didn’t show a statically significant difference in predicting treatment
failure this could be due to the good report of adherence in this study i.e. 98.5% .But  a
crossectional study conducted in the same hospitals previously  showed adherence report by care
giver in the past 7 days before the interview was (86.9%) .Looking this data the adherence
reported on the charts in our study might be not reliable. (22)
Fifty two (4.4%) of our patients developed OI which is less than the report in Jimma which was
7.3%.This could be the result of high lost in follow up in Jimma . similarly a cohort study in two
district hospitals of Cambodia showed the OI incidence declined from 14.4 %Pre HAART to 1.1
cases per 100 patient-years with HAART (18).The US Perinatal AIDS Collaborative
Transmission Study demonstrates the time of onset and incidence of bacterial OI has shown a
decrease trends in  the in the post HAART era than the pre HAART era (12). Similarly study
showed the rate of hospitalization markedly decreased in HAART era (13).
Anteretroviral drug substitutions were done in 119(ie10%) of all children studied. The majority
reason for substitution was toxicity for 94 (7.9%)  patients .This is similar to the  study in Jmma
(31) Patients who had substitution were in a higher probability of failure(AHR=1.695(1.053-
2.728)). This is similar to the Malawi study (26). This shows interruption of drug for toxicity will
lead to viral replication which intern result in treatment failure.
This study showed a significant association of treatment failure patients with chronic diarrhea
after ART initiation (AHR= 3.439(1.372-8.623)) this association also seen in Jimma study
relation (31) but they studied diarrhea at the time of initiation where as ours is after the ART
started. This study also showed a significant increase in the occurrence of treatment failure with
baseline chronic   malnutrition .This finding is in consistence with the study Tan Tock Seng
Hospital, Singalinepore where they found hazard ratio (HR) 2.19, 95% CI (1.29-3.73) P=0.004
for those with BMI<17 at base line and also the Jimma retrospective cohort showed 12.7(1-
154.5) P=0.06. (36, 40) for acute malnutrition at the start of ART (31,38)
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Regimen type didn’t predict treatment failure in our study in contrary to the Uganda study where
the independent viral failure in children was stavudine (d4T)/lamivudine (3TC)/Nevirapine
(NVP) versus zidovudine (ZDV)/3TC/efavirenz (EFV) with odds ratio [OR] = 2.59, 95% CI
(1.20 to 5.59); Other studies showed also Efavernce based vs Nevirapine based predicts
treatment failure but this also was not demonstrated In our study ( 20,34,35).
When we see the case detection rate 0f treatment failure it was low 24 (i.e14.35%) treatment
failures. The mean duration of treatment failures still on first line is 19.7 (± 14SD) months and
the duration of time from treatment failure to second line for those switched was
24±31.67month. Compared to the retrospective study in Malawi this time is less, where the
average time on ART before shifting to second-line ART regimen was reported 16.3 months. But
compared to the South Africa where the median time between virologic failure and switch was
4.6 months our study showed a delay in time of shift (26).
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7 Strengths of the Study
 This is the first large scale study which studied treatment failure in Ethiopia.
 Major public pediatric referral hospitals were included.
 Data quality was assured by using Nurses trained in ART as data collectors
8 Limitations of the Study
 Deaths and transferred out were not considered
 Retrospective nature of the study limits the important variables like seeing drug
interaction as treatment failure.
 Poor documentation variables made it impossible to see the effect of poor dose
adjustment for the weight of a child
 The effect of inttercurrent illness on CD4 couldn’t be controlled
9 Conclusion and Recommendation
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Conclusion
 chronic malnutrition at base line at base line was found to be a predictor of treatment
failure
 Chronic diarrhea after the start of ART associated with increased probability of having
treatment failure.
 Substitution of drugs for toxicity was found to increase the risk of having treatment
failure.
 Children who were having very CD4 less than 50 at base line were having increased
treatment failure probability.
 Sex , WHO clinical stage , disclosure status was not found to predict risk of treatment
failure adherence showed association among failure and non failure but it was not
statically significant.
 Majority of treatment failure patients were not detected and a significant delay in
switching to second line from the time of treatment failure identified.
Recommendation
 Prevention and treatment of children with malnutrition should be done in pre ART for all
children living with HIV
 Early initiation of treatment before sever immunosuppression is mandatory
 Prevention of chronic diarrhea with good personal hygiene, proper disposal of wastes and
identifying the cause of it and treating early is recommended
 Children who  require substitution of drugs should be closely observed for possible
treatment failure and delay in restart of the treatment should be minimized
 Early detection of treatment failures and timely switch tom second line is important
 Further prospective study is recommended to see the out come of those in second line
drugs.
36
10 Reference
1. Worldwide HIV & AIDS Statistics (cited on October 24,2010). Available
from:http://www.avert.org/worldstats.htm.
2. AIDS in Africa (Last Updated Sunday, November 29, 2009 cited October 24, 2010). Available
from: http://www.globalissues.org/article/90/aids-in-africa
3. Pediatric HIV and treatment of children living with Hiv (Accessed on Oct 31 2010). Available
from:http://www.who.int/hiv/topics/paediatric/en/index.html
4. Campaign to end pediatric hiv/aids in Africa 2008–2010 Agenda for Action August 2008(cited on
October 312010).Available from: http://www.globalaidsalliance.org/page
5. Towards universal access on HIV/AIDS globl launch of the 2010 report(cited october 9,2010).
Available from: http://www.unicef.org/esaro/TUA2010-Factsheet-final.pdf
6. Update as of end of February, 2010 MOH- FHAPCO ( cited October 7 1010).Available from:
www.HAPCO.GOV.et.
7. Pediatric Hiv/aids care and treatment in Ethiopia: results of a situational analysis: FMOH
ICAP   February 2006 Addis Ababa.
8. HIV/AIDS Treatment and Care(cited on November 5 2010).Available from:
http://www.avert.org/aids-hiv-treatment.htm
9.  Philippa M Musoke , Peter Mudiope, Linda N Barlow-Mosha, Patrick Ajuna, Danstan Bagenda
Michael M Mubiru, etal  Growth, immune and viral responses in HIV infected African children
37
receiving highly active antiretroviral therapy: a prospective cohort study. BMC Pediatr. 2010;
10: 56.
10. Verweel G, van Rossum AM, Hartwig NG, Wolfs TF, Scherpbier HJ, de Groot R. Treatment
with highly active antiretroviral therapy in human immunodeficiency virus type 1-infected
children is associated with a sustained effect on growth. Pediatrics. 2002; 109(2):E25 [PubMed]
[Cross Ref]
11.  Philimon Gona,  Russell B. Van Dyke,  Paige L. Williams, Wayne M. Dankner,  Miriam C.
Chernoff,  Sharon A. Nachman,  George R. Seage III,  Incidence of Opportunistic and Other
Infections in HIV-Infected Children in the HAART Era  JAMA. 2006; 296:292-300
12. Steven R. Nesheim, Bill G. Kapogiannis,  Minn M. Soe,  Kevin M. Sullivan,  Elaine Abrams,
John Farley,et al Trends in opportunistic infections in the pre-and post-highly active
antiretroviral therapy eras among HIV-infected children in the Perinatal AIDS Collaborative
Transmission Study, 1986-2004. PEDIATRICS Vol. 120 No. 1 July 2007, pp. 100-109
13. Thanyawee Puthanakit, Linda Aurpibul, Peninnah Oberdorfer, Noppadon Akarathum, Suparat
Kanjananit, Pornphun Wannarit etal  Hospitalization and Mortality among HIV-Infected
Children after Receiving Highly Active Antiretroviral Therapy, Clin Infect Dis. 2007 February
15; 44(4): 599–604.
14. Guidelines for Pediatric HIV/AIDS Care and Treatment in Ethiopia Federal HIV/AIDS
Prevention and Control Office Federal Ministry of Health July 2008.
15. WHO. Pocket book of hospital care for children: guidelines for the management of common
illnesses with limited resources. WHO, 2005. 209-213
16. WHO. Antiretroviral therapy for HIV infection in infants and children: towards universal access:
recommendations for a public health approach. WHO, 2006
17.  Vasan A, Hoos D, Mukherjee J, Farmer P, Rosenfield A, Perriens J. The pricing and
procurement of antiretroviral drugs: an observational study of data from the Global Fund.Bull
World Health Org 2006; 84:393–8.
38
18.Effectiveness of highly active antiretroviral therapy in HIV-positive children: evaluation at 12
months in a routine program in Cambodia: Global Health Sciences Literature Digest Published
February 25, 2008
19. Immune reconstitution inflammatory syndrome (cited 5 November 2010) .Available from:
http://en.wikipedia.org/wiki/Immune_reconstitution_inflammatory_syndrome
20. Kamya MR, Mayanja-Kizza H, Kambugu A, Bakeera-Kitaka S, Semitala F, Mwebaze-Songa P
etal Predictors of long-term viral failure among ugandan children and adults treated with
antiretroviral therapy. J Acquir Immune Defic Syndr. 2007 Oct 1; 46(2):187-93.
21. Barth RE, Tempelman HA, Smelt E, Wensing AM, Hoepelman AI, Geelen SP.Long-Term
Outcome of Children Receiving Antiretroviral Treatment in Rural South Africa: Substantial
Virologic Failure on First-Line Treatment. Pediatr Infect Dis J. 2010 Jul 13. [Epub ahead of
print]
22. Adult Antiretroviral therapy in resource limited settings a systemic review of first line ART
failure attrition rate.(accessed November 4 ,2010) available from:
http://retroconference.org/2010/PDFs/827.pdf
23. Sibhatu Biadgilign, Amare Deribew, Alemayehu Amberbir, and Kebede Deribe Adherence to
highly active antiretroviral therapy and its correlates among HIV infected pediatric patients in
Ethiopia .BMC Pediatr. 2008; 8: 53
24. Edna Iroha, Christopher Imokhuede Esezobor, Chinyere Ezeaka, Edamisan Olusoji Temiye,
Adebola Akinsulie adherence to antiretroviral therapy among HIV-infected children attending a
donor-funded clinic at a tertiary hospital in Nigeria. African Journal of AIDS Research (AJAR),
2010
25. Tadios Y, Davey G: Antiretroviral treatment adherence and its correlates among people living
with HIV/AIDS on highly active antiretroviral therapy in Addis Ababa, Ethiopia. EMJ 2006,
44(2):237-244.
39
26. W Chris Buck, Mark M Kabue, Peter N Kazembe and Mark W Kline Discontinuation of
standard first-line antiretroviral therapy in a cohort of 1434 Malawian children journal of the
International AIDS Society volume 2010, 13:31
27. Sutcliffe CG, van Dijk JH, Bolton C, Persaud D, Moss WJ. Effectiveness of antiretroviral
therapy among HIV-infected children in sub-Saharan Africa. Lancet Infect Dis. 2008; 8(8):477–
489. [PubMed] [Cross Ref])
28. A. davies, r. wood. van cutsem giddy. Eley  h. rabie, h. moultrie. technau10,12, a.
boulle1,virologic failure and second-line antiretroviral therapy  in children in south Africa: the
international epidemiologic databases to evaluate aids (idea) southern Africa collaboration
Conf HIV Pathog Treat 2009 Jul 19-22;5th
29. Bolton-Moore C, Cantrell RA, Chintu N, Stringer EM, Chi BH, Sinkala M,et al Clinical
outcomes and CD4 cell response in children receiving antiretroviral therapy at primary health
care facilities in Zambia. JAMA. 2007 Oct 24; 298(16):1888-99.
30. Puthanakit T, Kerr S, Ananworanich J, Bunupuradah T, Boonrak P, Sirisanthana V. Pattern and
predictors of immunologic recovery in human immunodeficiency virus-infected children
receiving non-nucleoside reverse transcriptase inhibitor-based highly active antiretroviral
therapy. Pediatr Infect Dis J. 2009;28(6):488–492. [PubMed] [Cross Ref).
31. Netsanet Workneh, , Tsinuel Girma,  Mirkuzie Woldie,  Immunologic And Clinical   Outcomes
Of Children On Haart: A Retrospective Cohort Analysis At Jimma University Specialized
Hospital    Ethiop J Health Sci.  Vol.19, No.2   July 2009:75-82
32. Watson DC, Farley JJ. Efficacy of and adherence to highly active antiretroviral therapy in
children infected with human immunodeficiency virus type 1. Pediatr Infect Dis J. 1999
Aug;18(8):682-9.
33. Rouet F, Fassinou P, Inwoley A. Long-term survival and immuno-virological response of
African HIV-1-infected children to highly active antiretroviral therapy regimens. AIDS, 2006;
20(18):2315-9
40
34. Emmett SD, Cunningham CK, Mmbaga BT, Kinabo GD, Schimana W, Swai ME,etal Predicting
virologic failure among HIV-1-infected children receiving antiretroviral therapy in Tanzania:
a cross-sectional study  .J Acquir Immune Defic Syndr. 2010 Aug 1; 54(4):368-75
35. Podjanee Jittamala, Thanyawee Puthanakit,  Sukrapee Chaiinseeard, and Virat Sirisanthana,
Predictors of Virologic Failure and Genotypic Resistance Mutation Patterns in Thai Children
Receiving Non-Nucleoside Reverse Transcriptase Inhibitor–Based Antiretroviral Therapy
Pediatr Infect Dis J 2009;28: 826–830
36. Fassinou P, Elenga N, Rouet F, Laguide R, Kouakoussui KA, Timite M, Blanche S, Msellati
P.Highly active antiretroviral therapies among HIV-1-infected children in Abidjan, Côte d'Ivoire.
AIDS. 2004 Sep 24; 18(14):1905-13.
37. Marconi VC, Sunpath H, Lu Z, et al. Prevalence of HIV-1 drug resistance after failure of a first
highly active antiretroviral therapy regimen in KwaZulu Natal, South Africa. Clin Infect Dis,
2008; 46 (10):1589-97
38. Paton NI, Sangeetha S, Earnest A, Bellamy R The impact of malnutrition on survival and the
CD4 count response in HIV-infected patients starting antiretroviral therapy. HIV Med. 2006
Jul;7(5):323-30.
39. Essajee SM, Kim M, Gonzalez C, Rigaud M, Kaul A, Chandwani S, etal Immunologic and
virologic responses to HAART in severely immunocompromised HIV-1-infected children.
AIDS. 1999; 13(18):2523–2532.  [PubMed]
40. Walker AS, Doerholt K, Sharland M, Gibb DM; Response to highly active antiretroviral therapy
varies with age: the UK and Ireland Collaborative HIV Paediatric Study. AIDS. 2004 Sep 24;
18(14):1915-24
41. ART Patient Uptake Status Update Sene (1-30 ) 2002 E.C (June 8, 2010 - July 7, 2010 )
Reported by : MSH/SPS
41
Annexes
Annex I. Data collection Format
I. Patient identification
1. Facility Name
2. Patient card number
3. Unique Art number
II. Socio demographic Factors:
Number Question Response category Code
4 Age Month ….
5 sex 1.Female
2.Male
6 Primary care taker 1) father
2) mother
3) grand parent
4)sibling
5)relative
6)neighbor
7) orphanage
8) other
7 Serology of care
giver
1) Positive
2) Negative
3) unknown
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III. Clinical feature of patient:
Anthropomethry
Number Month
after  Art
started
0 6 12 18 24 30 36 42 48 52 Code
8 Wt
9 Ht
10 HC
Number Question Response category Code
11 Date of confirmation of Hiv status Date /moth/year
12 Previous PMTC   for infant 1) yes
2) No
3) unknown
13 If yes on q 12 1) NVP
2) NVP and AZT
14 ART prophylaxis for PMTCT the
mother
1) SNVP
2) SNVP +AZT
3) none
15 Type of HIV TEST
a)Rapid HIV (for >18month)  or Elsa
c) Pcr less than 18 month
16 Who stage   on Art initation 1)I
43
2)II
3)III
4)IV
17 Date of ART started Date/moth/year
18 Reason for starting ART initation 1) WHO STAGE
2) Immunolgic only
3) A and b
4) Virologic
5) A, b ,and c
6=the age of the child is <1year
19 Type of ART 1=4a ( DRT +3Tc +NVp  )
2=4b (D4T+3Tc + EVs  )
3=4c( AZT + 3TC+ NVp)
4=4d( AZT+3Tc +EVs)
5=kaletra based /other
20 Dose form 1) syrup
2) tablet
3) both used at different times
21 Drug form  type 1) fixed dose  combination
2) separate
3) both used previously
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22 Was any time the Art drugs
substituted
1.yes
2.No
23 Drug
substitution reason
1)Toxicity
2)Failure
3)Other diseases like tb
4)Age
5)Other reason
6)Not specified
24 If on Q23 Drug
substitution reason date
Date/Mon/year of switch
25 If Q 23 is yes to which regimen
changed refer 19
26 New OI 1) Yes
2) No
27 Tuberculosis after start of ART   if
yes  what type
1) Yes
2) No
28 If Q 26 yes 1) Pulmonary
2)Extrapulmonary
3) Disseminated tb
45
29 Treatment failure 1)yes
2)No
30 If question number 27 is yes 1) Who stage back ward
2)  growth failure despite nutritional
support
3) developmental regression /delay
4) new or recurrent OI
31 Treatment failure 1 clinical
2 Immunologic
3 Virologic
4 1 and 2
5 2 and 3
6 1 and 3
7 1,2,3
32 Chronic diarrhea or persistent
diarrhea
1. Yes ……
2.No………
33 If Q 30 yes if yes  duration
34 Disclosure done: 1)  yes ,
2) no
3) not applicable if age <8
4) not documented
35 Developmental milestone 1)appropriate
2)Delay
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3)Regression
4)not documented
36 Switch to second line 1)yes
2)No
37 Date of swich Date/month/year
IV. Laboratory and adherence
Month At Art
start
6 12 18 24 30 36 42 48 52 code
CD4 number if child
is > 5years
CD4 % is less than
5year
Immunologic
category at initiation
of therapy
Adherence report eof
the cumulative 6
month
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Annex II: Consent Form
This is a study conducted for partial fulfillment of a post graduate program requirements at
University of Gondar and Addis Continental Institute of Public Health joint MPH Program. The
main objective of this study is to assess the magnitude of first-line ART failure and its predictors
among HIV-infected pediatric patients on ART registered at major public pediatric referral
hospitals in Addis Ababa. Such assessment will help identify potential challenges for program’s
success and provide useful information for designing interventions against the challenges. It will
also help in providing an insight to the program’s performance and clients’ follow up status in
the hospital. Therefore, the hospital’s participation and collaboration is very much helpful in
generating the required information and will be very much appreciated.
In this study data will be collected from the Pre-ART, ART registers and follow up forms using a
form developed for this study. Information regarding socio demographic characteristics, clinical
and laboratory data, follow up status and information on outcomes of each client in terms of
first-line ART failure will be collected from the registers. Information regarding any specific
personal identifiers like the name of the clients will not be collected and information generated
will be disclosed in totality. In addition, confidentiality of any personal information will be
maintained throughout the study process and no unauthorized access to the information is
allowed.
Finally, the hospital has all the right to refuse to participate in this study and shall withdraw from
the study at any time. If they have any questions or need further information regarding the
planned study you are free to get clarifications the principal investigator or  from the institution
or through the following addresses; Addis Continental Institute of Public Health, Tell
0116526853 (Dr. Alemayehu Worku – the primary advisor of this research) or Dr Tigist Bacha,
Tell.0911676304 (the principal investigator).Therefore, if you would like to participate in this
study, would you please confirm it by signing here . Thank you very much
Participant: ------------------------------------- Principal investigator: --------------------------------
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Annex III
የፋቃደኝናት መጠያቅያ ቅጽ
ÃI Ø“ƒ uÑA”Å` ¿”y`c=+  “ u›Ç=e ¢”ƒ’@” M ¾TIu[cw Ö?“ ›Övup ›=”e+ƒ¿ƒ Ò`
uS}vuር KÉI[ U[n ¾SS[mÁ îG<õ ’¨< ::
¾Ø“~ ª“ ›LT u›Ç=e ›uv uT>Ñ˜ ¾S”Óeƒ JeፒKA‹ ¾}S²Ñu< Ÿ›?‹ ›Ã y= Ò` ›w[¨<
uT>•\ Ií“ƒ LÃ ያ}¢[ ሲJ” ›ላT¨<U uSËS]Á Å[ጃ ¾T>WÖ< ¾ì[ ›?‹ ›Ã y= SÉኃ’>ƒ
¡iðƒ SÖ”” TØ“ƒ c=J”  “ ¾¡ió~ KT>ÁSÖ< ¾‹Ó\ ›Sላካ‹ U¡”Á„‹” TØ“ƒ
’¨< ::
ÃI Ø“ƒ K}KÁ¿ uኤ‹ ›Ã y= LÃ KT>W\ ¾eŸ?ƒ ð ˜ G<’@ ­‹” KSK¾ƒ  “   ”Ç=G<U
Kð ˜ G<’@ ­‡ SðƒH@ Kመp[î ¾T>[Æ S[ጃ­‹” KSeÖƒ ’¨< :: eK²=I }ðLÑ>
S[Í­‹” uScwcw Y^ LÃ ¾Jeፒ KA‡ }Xƒö“ ƒww` u×U ¾T>ÅÑፍ ’¨< ::
u²=I Ø“ƒ S[Í­‹ ¾T>cucu<ƒ ¾pÉS ì[ ›?‹ ›Ã y= I¡U“ SÉG’>ƒ IS<T”
ŸS¨cÇቸ¨< uòት ŸT>S²Ñwuƒ S´Ñw LÃ  “ c=ጀU\  “ ŸËS\U uኋላ uT>S²Ñu<ƒ
S´Ñw“ ካ`É }¨eÊ K²=I u}²ÒË ö`U LÃ ÃcuduM::
የሚሰበሰበው መረጃ ይዘት የ ማሚውን የማህበረዊና የጤንነት ሁኔታ እና የላብራቶ] መረጃዎችን
የክትትል ሁኔታ የህክምና ውጤት ደረጃና ከየመዝገቦቹ ይካተታሉ:: ተማሚው የግል ገላጭ የሆነ
ማለትም የበሽተኛው ስም በመሰብሰብያ ወረቀት ላይ አይሰፍርም::  በጥና~ ውጤት የሚገኘው መረጃ
በግለሰብ ደረጃ ሳይሆን በአጠቃላይ ይፋ ይሆናል፡፡ የበሽታኞች ምስጥር በሙሉ በድብቅ በጥናቱ ቆይታ
H>ደት ሁሉ እንደተጠበቁ ይቆያሉ በጥናቱ እንÇ=ሰሩ የልተ"ተቱ ሰዎች መረጃዎችን እንÇ=ያገኙ
አይፈቀድላቸውም፡፡
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በመጨረሻም የሆስፒታሎቹ ሙሉ ለሙሉ በጥናቱ ላይ ላለመሳተፍ መብት አላቸው፡፡ በጥናቱ ሂደት
መዕከልም የTቋረጥ መብት አላቸው ለማንኛውም ጥያቄና መረጃ ጥናቱን በተመለከተ ከጥናቱ ዋና
አT"ሪ እንÇ=ሁም ከጥናቱ ዋና አጥኝ ወይም ከአÇ=ስ ኮንትኔታል እኒስ+ƒÄት ከታች በተዘረዘሩት
አድረሻዎች ለመነጋገር ማብራሪያ ማግኛት ይችላሉ፡፡
ዶ/ር አለማየሁ ወርቁ   /ዋና አማካሪ / ዐ116526853
ዶ/ር ትዕግስት ባጫ /ዋና አጥኝ/  0911676304
በዚህ ጥናት ለመሳተፍ ፈቃደኛ ከሆኑ እባክዎን በፊርማዎ የረÒግጡ
ከምስጋና ጋር
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